# ClinicalTrials.gov record NCT03374956

> PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03374956-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03374956-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03374956-liraglutide-v1.json
- Content SHA-256: `802b5cb09c23254f11240e125e918dca231b678b5c677926b1629ae7e50de3ff`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03374956 ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03374956-2023-07-18-339e221e46e4`](#source-ctg-observation-nct03374956-2023-07-18-339e221e46e4))

## Sources

<a id="source-ctg-observation-nct03374956-2023-07-18-339e221e46e4"></a>
- **ClinicalTrials.gov record NCT03374956 · retained source version 2023-07-18:339e221e46e42c79e8bc5a011202507dc12637bd22eba26a877a62009a6ed5a9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03374956) (`ctg-observation-nct03374956-2023-07-18-339e221e46e4`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03374956." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03374956-liraglutide-v1.json SHA-256: 802b5cb09c23254f11240e125e918dca231b678b5c677926b1629ae7e50de3ff.